別添5

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書　籍　名	出版社名	出版地	出版年	ページ
本田晃、黒川峰夫	高齢者骨髄異形成症候群に対する同種造血幹細胞移植v.s.脱メチル化薬		血液内科	科学評論社	東京	2022	
本田晃、黒川峰夫	エルドハイム・チェスター病（Erdheim-Chester deisease:ECD）		Medhical Practice	文光堂	東京	2022	
正本庸介、黒川峰夫	T細胞性非ホジキンリンパ腫に対する抗体医薬の種類と臨床的意義		血液内科	科学評論社	東京	2022	
正本庸介、黒川峰夫	肥満症による感染症重症化機構		医学のあゆみ	医歯薬出版株式会社	東京	2022	
宮内　将、黒川峰夫	Efficient production of human neutrophils from iPSCs that prevent murine lethal infection with immune cell recruitment		実験医学	羊土社	東京	2022	1428-1431

黒川峰夫、梅澤明弘、森下竜一、岡野栄之	座談会：わが国がリードする再生医療の最前線		日本医師会雑誌	日本医師会	東京	2022	545-555
黒川峰夫	造血器腫瘍に対する最新の治療		日本検査血液学会雑誌	日本検査血液学会	東京	2022	441-448

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kato K, Yabe H, Shimozawa N, Adachi S, Kurokawa M, Hashii Y, Sato A, Yoshida N, Kaga M, Onodera O, Kato S, Atsuta Y,	Stem cell transplantation for pediatric patients with adrenoleukodystrophy: a nationwide retrospective	Pediatric Transplantation	26(1)	e14125	2022
Sato M, Honda A, Maki H, Toyama K, Yamaguchi R, Ikeda M, Moriya K, and Kurokawa M.	Successful treatment of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa after allogeneic hematopoietic stem cell transplantation with	International Journal of Journal of Infection and Chemothera	28(1)	91-94	2022
Murakami D, Maki H, Matsuda K, Masamoto Y, Suzuki F, Amemiya S, Osawa K, Hinata M, Ikemura M, Ushiku T, and Kurokawa M.	Cerebral Toxoplasmosis complicating lymphoplasmacytic lymphoma in partial remission.	Journal of Infection and Chemotherapy	28(2)	279-282	2022
Takano H, Yasunaga M, Yamazaki I, Nishikawa M, Masamoto Y, Kawakami M, Yatomi Y, and Kurokawa M.	Degenerated mitochondria in leukemic blast appeared as granules on May-Grunwald-Giemsa staining.	Annals of Hematology	101(5)	1135-1136	2022

Ebisawa K, Honda A, Chiba A, Masamoto Y, Okazaki H, and Kurokawa M.	High D-index during mobilization predicts poor mobilization of CD34+ cells after anti-lymphoma salvage chemotherapy.	Journal of Clinical Apheresis	37(1)	4-12	2022
Hayashida H, Honda A, Hino T, Mizuno H, Toyama K, and Kurokawa M.	A case of thymoma showing significant tumor reduction after anti-thymocyte globulin.	General Thoracic and Cardiovascular Surgery	70(1):	96-99	2022
Sato M, Yasunaga M, Ohzu M, Toyama K, Nakazaki K, Nakahara F, Kubo T, Okura N, Abe O, and Kurokawa M.	Successful diagnosis of veno-occlusive disease caused by inotuzumab ozogamicin through minimal-invasive	Annals of Hematology	101(5)	1153-1155	2022
Hino T, Honda A, Shimura A, Masamoto Y, and Kurokawa M.	R-GCD regimen in elderly patients with relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma: a retrospective single-center	International Journal of Hematology	115(2)	296-297	2022
Kurihara Y, Mizuno H, Honda A, Shimura A, Fujioka Y, Maki H, and Kurokawa M.	CCDC88C-FLT3 gene fusion in CD34-positive hematopoietic stem and multi-lineage cells in myeloid/lymphoid neoplasm with eosinophilia.	Journal of Cellular and Molecular Medicine	26(3)	950-952	2022
Matsuda K, Jo T, Shimura A, Honda A, Masamoto Y, Matsui H, Fushimi K, Yasunaga H, and Kurokawa M.	Risk of febrile neutropenia in very elderly patients aged ≥80 years who received the first cycle of R-CHOP regimen: a nationwide real-world study in Japan.	British Journal of Haematology			2022

Higo T, Suzuki Y, Sato M, Koya J, Mizuno H, Miyauchi M, Masamoto Y, Kataoka K, Sumitomo Y, Tsuruta-Kishino T, Sato T, and Kurokawa M.	Heterozygous Dnmt3a R878C induces expansion of quiescent hematopoietic stem cell pool.	Experimental Hematology		S0301-472X(22)00076-5	2022
Nakazaki K, Yoshida M, Masamoto Y, Shinozaki-Ushiku A, Ikemura M, Hisamoto T, Yasunaga M, Sato S, and Kurokawa M.	Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment against atopic dermatitis.	International Journal of Hematology			2022
Oyama T, Taoka K, Chiba A, Matsuda K, Maki H, Masamoto Y, and Kurokawa M.	A case of Bing-Neel syndrome successfully treated with tirabrutinib.	Internal Medicine			2022
Murakami D, Matsuda K, Honda A, Masamoto Y, and Kurokawa M.	Severe infections and renal dysfunction during immunosuppressive therapy with cyclosporine A for aplastic anemia.	International Journal of Hematology			2022
Ebisawa K, Masamoto Y, Yagi K, and Kurokawa M.	A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate.	Annals of Hematology			2022
Fukui Y, Honda A, Takano H, Obo T, Mizuno H, Masamoto Y, and Kurokawa M.	Severe autoimmune pancytopenia after autologous hematopoietic stem cell transplantation for Hodgkin lymphoma.	Journal of Clinical and Experimental Hematopathology			2022

Miyashita H, Taoka K, Kume A, Ushiku A, Ushiku T, Toyama K, and Kurokawa M.	Clinical usefulness of a novel classification of T cell distribution patterns in the tumor microenvironment of follicular lymphoma to detect transformation.	Annals of Haematology			2022
Masuda Y, Oyama T, Nakazaki K, Nakai Y, Sasaki K, Matsuda K, Masamoto Y, and Kurokawa M.	Aortitis associated with prophylactic short-acting granulocyte colony-stimulating factor administration: a case report and review of the literature.	Internal Medicine			2022
Masamoto Y, Taoka K, Maki H, and Kurokawa M.	Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.	Annals of Hematology			2022
Oyama T, Taoka K, Chiba A, Masamoto Y, Ikemura M, Honda A, Maki H, and Kurokawa M.	Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion.	International Journal of Hematology			2022
Masamoto Y, Chiba A, Mizuno H, Hino T, Hayashida H, Sato T, Bando M, Shirahige K, and Kurokawa M.	EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistance and immune-suppressive environment.	Blood Advances			2022
Oyama T, Matsuda K, Honda A, Yasunaga M, Nakazaki K, Maki H, Masamoto Y, and Kurokawa M.	Long-term follow-up of central nervous system relapse in patients with acute promyelocytic leukemia.	Leukemia and Lymphoma			2022

Oyama T, Matsuda K, Honda A, Maki H, Masamoto Y, Murakami D, Toya T, Sakurai M, Kataoka K, Doki N, and Kurokawa M.	Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.	International Journal of Hematology			2022
Matsuda K, Oyama T, Maki H, Nakazaki K, Yasunaga M, Honda A, Masamoto Y, and Kurokawa M.	Prompt initiation of conventional chemotherapy to avoid early death in patients with newly diagnosed acute promyelocytic leukemia.	Internal Medicine			2022
Masamoto Y, Shimura A, Honda A, Taoka K, Maki H, and Kurokawa M.	Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.	Annals of Hematology			2022
Yoshida M, Morita K, Fukushima H, Jona M, Nishikawa M, Yatomi Y, Kishino Y, Iwasaki A, Ushiku T, Imadome K, Honda A, Maki H, and Kurokawa M.	Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma.	International Journal of Hematology			2022
Yoshida M, Matsuda K, Endo K, Honda A, Maki H, Taoka K, Masamoto Y, Wakimoto Y, Jubishi D, Moriya K, and Kurokawa M.	Toxic shock like syndrome caused by Streptococcus agalactiae bacteremia during treatment for multiple myeloma.	Journal of Infection and Chemotherapy			2022
Yoshida M, Matsuda K, Taoka K, Honda A, Maki H, Masamoto Y, Jona M, Nishikawa M, Yatomi Y, and Kurokawa M.	Expansion of large granular lymphocytes after autologous hematopoietic stem cell transplantation.	International Journal of Hematology			2022

Obo T, Morita K, Sumida Y, Nakazaki-Watadani K, Ikemura M, Yasaka K, Abe O, Takami H, Takayanagi S, Tanaka S, Maki H, Masamoto Y, Miwa A and Kurokawa M.	Isolated relapse of plasma cell leukemia in the central nervous systems, a case report and literature review.	International Journal of Hematology			2022
Fukushima H, Morita K, Ikemura M, Tanaka M, Nakai Y, Maki H, Suzuki T, Mizuno S, Nakai Y, and Kurokawa M.	Acute pancreatitis as the initial manifestation of acute myeloid leukemia with chromosome 16 rearrangements.	International Journal of Hematology			2022
Honda Y, Muramatsu H, Nanjo Y, Hirabayashi S, Meguro T, Yoshida N, Kakuda H, Ozono S, Wakamatsu M, Moritake H, Yasui M, Sano H, Manabe A, Sakashita K	A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.	Int J Hematol	115	263-268	2022
Hama A, Hasegawa D, Manabe A, Nozawa K, Narita A, Muramatsu H, Kosaka Y, Kobayashi M, Koh K, Takahashi Y, Watanabe K, Ohara A, Ito M, Kojima S	Prospective validation of the provisional entity of refractory cytopenia of childhood, proposed by the World Health Organization.	Br J Haematol	196	1031-1039	2022
Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, Cario G, Cazzaniga G, Escherich G, Harrison C, Heyman M, Hunger S, Kiss C, Liu HC, Locatelli F, Loh M, Manabe A, Mann G, Pieters R, Pui CH, Rives S, Schmiegelow K, Silverman L, Stary J, Vora A, Brown P	Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium	Blood	139	1785-1793	2022

Attarbaschi A, Moricke A, Harrison CJ, Mann G, Baruchel A, Benoit Y, Conter V, Devidas M, Elitzur S, Escherich G, Hunger S, Horibe K, Manabe A, Loh M, Pieters R, Schmiegelow K, Silverman LB, Stary J, Vora A, Pui CH, Schrappe M, Zimmermann M	Outcome of childhood non-infant acute lymphoblastic leukemia with 11q23/*KMT2A*-rearrangements in a modern therapy era – a retrospective international study of 629 patients.	J Clin Oncol	41	1404-1422	2022
Elitzur S, Vora A, Burkhardt B, Inaba H, Attaerbaschi A, Baruchel A, Escherich G, Gibson B, Liu HC, Loh M, Moorman A, Moericke A, Pieters R, Uyttebroeck A, Baird S, Bartram J, Barzilai-Birenboim S, Batra S, Ben-Harosh M, Bertrand Y, Buitenkamp T, Caldwell K, Drut R, Geerlinks A, Gilad G, Grainger J, Haouy S, Heaney N, Huang M, Ingham D, Krenova Z, Kuhlen M, Lehrnbecher T, Manabe A, Niggli F, Paris C, Revel-Vilk S, Rohrlich P, Sinno M, Szczepanski T, Tamesberger M, Warrier R, Wolfl M, Nirel R, Izrael S, Borkhardt A, Schmiegelow K	EBV-driven lymphoid neoplasms associated with ALL maintenance therapy	Blood	141	743-755	2023
Ohki K, Butler E, Kiyokawa N, Hirabayashi S, Bergmann A, Moericke A, Boer J, Cave H, Cazzaniga G, Yeoh A, Sanada M, Imamura T, Inaba H, Mullighan C, Loh M, Norén-Nyström U, Shih LY, Zaliova	Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: A retrospective study by the Ponte di Legno Childhood ALL Working Group	Leukemia	37	212-216	2023

M, Pui CH, Haas O, Harrison C, Moorman A, Manabe A					
Sato A. Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K	Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy on newly diagnosed T-cell acute lymphoblastic leukemia in children and young adults: a nationwide, multicenter, phase II trial including randomization in the very high-risk group	Lancet Haematol			2023
Ueki M, Sakamoto K, Nishioka N, Ohata H, Nobuta T, Takezaki S, Manabe A, Yamada M	Rheumatologic manifestations with elevated levels of IL-6, IL-17, and IL-23 in a patient with scurvy	Mod Rheumatol Case Rep			2023
Ishikawa M, Hanami Y, Yamamoto T.	Infantile urticaria pigmentosa with eosinophilic infiltration: a case report.	Indian J Dermatol	67	482	2022
Takahashi Y, Ishida H, Imamura T, Tamefusa K, Suenobu S, Usami I, Yumura-Yagi K, Hasegawa D, Nishimura S, Suzuki N, Hashii Y, Deguchi T, Moriya-Saito A, Kosaka Y, Kato K, Kobayashi R, Kawasaki H, Hori H, Sato A, Kudo T, Nakahata T, Oda M, Hara J, Horibe K	JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia	Int J Hematol			2022

Kida D, Hashimoto H, Saito AM, Kito Y, Hattori Y, Terabe K, Mori K, Takahashi N, Tomita Y	The Efficacy and Safety of a Novel Extramedullary Guide Coordinated with 3D Surgical Assistive Software for Total Knee Arthroplasty: an Open-Label Single-Arm Trial	Kurume Med J	67(1)	31-40	2022
Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Horibe K, Koh K, Miyazaki Y, Watanabe A	Impact of Nelarabine, Intensive L-Asparaginase, and Protracted Intrathecal Therapy on Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group and the Japan Adult Leukemia Study Group	Blood	138	3393	2021
Yamada T, Kuwai T, Sasaki Y, Sakakibara Y, Uraoka T, Kato M, Watanabe N, Kimura T, Kada A, Saito AM, Harada N	Potential for replacing warfarin with a direct oral anticoagulant for endoscopic mucosal resection in the colorectum: a multicenter,open-label, randomized controlled trial	DEN Open			2022
Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Ebi N, Inoue A, Kurata T, Okamoto I, Yamaguchi M, Harada T, Seike M, Ando M, Saito AM, Kubota K, Takenoyama M, Seto T, Yamamoto N, Gemma A	Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial	The Lancet Healthy Longevity	3(4)	e791	2022

Matsumura T, Hashimoto H, Sekimizu M, Saito AM, Motoyoshi Y, Nakamura A, Kuru S, Fukudome T, Segawa K, Takahashi T, Tamura T, Komori T, Watanabe C, Asakura M, Kimura K, Iwata Y	Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study	Orphanet J Rare Dis	17(1)	201	2022
Nakamura K, Saito AM, Ueda K, Ueda K, Yoshihara K, Hiramatsu N, Yamashita Y, Kusaka Y, Ui H	Risk-based Approach to Determine the Need for an Audit:In What Situations Should an Audit Be Performed?	Jpn. J. Pharmacol. Ther	53(3)	49-53	2022
Shima H, Kada A, Tanizawa A, Sato I, Tono C, Ito M, Yuza Y, Watanabe A, Kamibeppu K, Uryu H, Koh K, Imai C, Yoshida N, Koga Y, Fujita N, Saito AM, Adachi S, Ishii E, Shimada H	Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia	Pediatr Blood Cancer	69(8)	e29699	2022
Tomizawa D, Tsujimoto SI, Tanaka S, Matsubayashi J, Aoki T, Iwamoto S, Hasegawa D, Nagai K, Nakashima K, Kawaguchi K, Deguchi T, Kiyokawa N, Ohki K, Hiramatsu H, Shiba N, Terui K, Saito AM, Kato M, Taga T, Koshinaga T, Adachi S	A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20)	Jpn J Clin Oncol	52(10)	1225-1231	2022
Edahiro Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Kada A, Saito	Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study	Int J Hematol	116(5)	696-711	2022

AM, Shimoda K, Sugimoto Y, Kurokawa T, Tomita A, Hashimoto Y, Akashi K, Matsumura I, Takenaka K, Komatsu N					
Nakayama H, Ogawa C, Sekimizu M, Fujisaki H, Kosaka Y, Hashimoto H, Saito AM, Horibe K	A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)	Int J Hematol	116(4)	612-621	2022
Suzukawa M, Ohta K, Hashimoto H, Oyamada Y, Miki M, Ogawara M, Inoue Y, Saito AM, Fukutomi Y, Kobayashi N, Taniguchi M	NHOM-Asthma Study Group. Characterization and cluster analyses of elderly asthma in comparison with nonelderly patients with asthma in Japan	Ann Allergy Asthma Immunol			2023
Suzukawa M, Ohta K, Fukutomi Y, Hashimoto H, Endo T, Abe M, Kamide Y, Yoshida M, Kikuchi Y, Kita T, Chibana K, Tanimoto Y, Hyodo K, Takata S, Inui T, Yasui M, Harada Y, Sato T, Sakakibara Y, Minakata Y, Inoue Y, Tamaki S, Shinohara T, Takami K, Tsubakihara M, Oki M, Wakamatsu K, Horiba M, Ideura G, Hidaka K, Saito AM, Kobayashi N, Taniguchi M	Classifications of moderate to severe asthma phenotypes in Japan and analysis of serum biomarkers: A Nationwide Cohort Study in Japan (NHOM Asthma Study)	Allergol Int	72(1)	63-74	2023